UAE Chronic Cough Therapeutics Market Analysis

UAE Chronic Cough Therapeutics Market Executive Summary

UAE Chronic Cough Therapeutics Market was valued at $32 Mn in 2022 and is estimated to reach $63 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period.

Chronic cough is a persistent cough that lasts for an extended period, typically lasting more than eight weeks. Unlike acute coughs, which are often associated with infections or other short-term conditions, chronic cough can be a symptom of an underlying and more persistent health issue. Common causes of chronic cough include respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications. Identifying and addressing the underlying cause of chronic cough through a thorough medical evaluation is important, as treating the root issue is crucial for effective management. Chronic cough can significantly impact an individual's quality of life and may require a multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists for comprehensive care.

The prevalence of chronic cough and related respiratory conditions in the United Arab Emirates (UAE) is a significant public health concern. The prevalence of asthma was 12.3%, chronic bronchitis was 1.8%, and emphysema was 0.5%. Additionally, 34.8% of the adolescents reported a dry nocturnal cough in the past year. A prevalence of chronic bronchitis of 0.6% is seen in the UAE. Furthermore, the prevalence of chronic obstructive pulmonary disease (COPD) in the UAE was found to range from 3.7% to 5.3% in the Middle East and North Africa region.

Pfizer has unveiled plans for a novel over-the-counter (OTC) cough syrup formulation, merging dextromethorphan and guaifenesin. This formulation is designed to address both cough and mucus production. Additionally, Boehringer Ingelheim has entered into a strategic partnership with a digital health company to create a mobile application tailored for managing chronic cough. The app aims to offer features such as symptom tracking, educational resources, and potential connections to healthcare professionals, enhancing the overall management of chronic cough for users.

Market Dynamics

Market Growth Drivers

Aging Population: The expansion of the aging population holds significant importance in the UAE, with estimates projecting a rise to 16% by 2050, signifying a noteworthy alteration in the age demographics. This growing aging population in the UAE plays a pivotal role in driving the expansion of the chronic cough therapeutics market. As individuals age, there is an elevated susceptibility to respiratory conditions, contributing to an increased prevalence of chronic cough within this demographic.

Changing Lifestyles and Environmental Factors: Lifestyle changes and environmental factors, such as air pollution and exposure to allergens, can contribute to the increase in chronic cough cases. The market responds to these challenges by providing therapeutics to address the symptoms and underlying causes.

Prevalence of Chronic Respiratory Conditions: The high prevalence of chronic respiratory conditions within the population contributes significantly to the demand for chronic cough therapeutics. As chronic cough is often associated with respiratory issues, the market experiences growth due to the need for effective treatment options.

Market Restraints

Cultural and Social Stigmas: Hesitancy in seeking medical attention may arise from cultural and social stigmas linked to respiratory conditions. Societal perceptions may discourage individuals from openly discussing or addressing chronic coughs, resulting in a tendency for underreporting and undertreatment of the condition.

Limited Awareness and Education: Lack of awareness and education about chronic cough and available treatment options among both healthcare professionals and the general population can hinder the market. This may result in delayed diagnosis and inadequate management of the condition.

Healthcare Infrastructure Challenges: Challenges in the healthcare infrastructure, including limited access to specialized care and diagnostic facilities, can impede the effective diagnosis and treatment of chronic cough. Insufficient healthcare resources may hinder the market's growth potential.

Healthcare Policies and Regulatory Landscape

In the United Arab Emirates (UAE), the oversight and regulation of treatment drugs are primarily coordinated by key entities such as the Ministry of Health and Prevention (MOHAP), Health Authority Abu Dhabi (HAAD), Dubai Health Authority (DHA), Emirates Health Services Establishment (EHSE), and the Pharmaceutical Services Department (PSD). MOHAP, serving as a central regulatory authority, holds a crucial role in shaping and enforcing healthcare policies to guarantee the safety, effectiveness, and quality of pharmaceuticals. Additionally, regional health authorities like HAAD and DHA manage healthcare services, including drug regulations, within their respective emirates. EHSE contributes to federal-level regulations, while PSD, operating under MOHAP, concentrates on pharmaceutical-related activities. The Centralized Procurement Office (CPO) is actively engaged in acquiring pharmaceuticals for public healthcare facilities, ensuring compliance with regulatory standards.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK)
• Pfizer
• McNeil Consumer Healthcare (Johnson & Johnson)
• Procter & Gamble (P&G)
• Reckitt Benckiser Group
• Perrigo Company
• Medtech Products Inc.
• Bionpharma Inc.
• A. Vogel Canada Inc.
• Jamieson Laboratories